#VisualAbstract: Immune checkpoint inhibitors are equally effective for younger and older patients with relapsed or metastatic head and neck squamous cell carcinomas
Click to read this study in the European Journal of Cancer.
Click to read this study in the European Journal of Cancer.
Click to read this study in JAMA Network Open.
Patients receiving adjuvant pembrolizumab after nephrectomy for renal-cell carcinoma showed significantly improved disease-free survival compared to patients receiving placebo treatment. ...
1. Patients receiving adjuvant pembrolizumab after nephrectomy for renal-cell carcinoma showed significantly improved disease-free survival compared to patients receiving placebo ...
Click to read the study in The Lancet.
Click to read the study in the European Journal of Cancer.
Click to read the study in The Lancet Oncology.
1. Concomitant pembrolizumab plus chemoradiation therapy was associated with improved antitumor activity and safety profile in patients with previously untreated, ...
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.